<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Insulin Regular</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00030</strong>&#160; (BIOD00105, BTD00105, DB01383)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved, experimental, investigational</td></tr><tr><th>Description</th><td><p>Insulin regular is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant <span class="caps">DNA</span> techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00030.png?1266600386"><img alt="Db00030" src="/system/protein_structures/thumb/DB00030.png?1266600386"></a></td></tr><tr><th>Protein chemical formula</th><td>C<sub>257</sub>H<sub>383</sub>N<sub>65</sub>O<sub>77</sub>S<sub>6</sub></td></tr><tr><th>Protein average weight</th><td>5808 Daltons </td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;A chain
GIVEQCCTSICSLYQLENYCN</pre><pre class="sequence">&gt;B chain
FVNQHLCGSHLVEALYLVCGERGFFYTPKT</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00030/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Insulin human </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Humulin R</td><td>Eli Lilly and Company</td></tr><tr><td>Novolin R</td><td>Novo Nordisk</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Humulin 20/80</td><td>20% human insulin injection; 80%  human insulin isophane suspension</td></tr><tr><td>Humulin 50/50 </td><td>50% human insulin isophane suspension; 50% human insulin injection</td></tr><tr><td>Humulin 70/30 </td><td>70% human insulin isophane suspension; 30% human insulin injection</td></tr><tr><td>Humulin 70/30 Pen </td><td>70% human insulin isophane suspension; 30% human insulin injection</td></tr><tr><td>Novolin ge 30/70</td><td>30% human insulin injection; 70%  human insulin isophane suspension</td></tr><tr><td>Novolin ge 40/60</td><td>40% human insulin injection; 60%  human insulin isophane suspension</td></tr><tr><td>Novolin ge 50/50</td><td>50% human insulin injection; 50%  human insulin isophane suspension</td></tr><tr><td>Novolin70/30</td><td>Insulin Regular + Insulin, isophane</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antidiabetic-agents">Antidiabetic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>11061-68-0</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. </td></tr><tr><th>Pharmacodynamics</th><td>Insulin regular is a short-acting insulin. When subcutaneously administered, the onset of action (as evidenced by a decrease in glucose level) occurs 30 minutes post-dose. Maximal effect occurs between 1.5 and 3.5 hours post-dose. The glucose-lowering effect occurs 8 hours post-dose. Compared to other rapid-acting insulin analogs, insulin regular has a slower onset of action and longer duration of action. </td></tr><tr><th>Mechanism of action</th><td>The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.</td></tr><tr><th>Absorption</th><td>Insulin is generally well absorbed. </td></tr><tr><th>Volume of distribution</th><td><p>0.15 L/kg</p></td></tr><tr><th>Protein binding</th><td>5% protein bound </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Hypoglycemia is one of the most frequent adverse events experienced by insulin users. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novo nordisk inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li>DispenseXpress Inc.</li>
<li><a href="http://www.lilly.com">Eli Lilly &amp; Co.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.intervet.ca">Intervet International</a></li>
<li><a href="http://www.novonordisk.com">Novo Nordisk Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection</td><td>Subcutaneous</td><td>100 units/mL; 500 units/mL</td></tr></tbody></table></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06655">Liraglutide</a></td><td>Coadministration may increase the risk of hypoglycemia. A lower dose of the antidiabetic agent may be needed.
</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>